Scilex Holding Co
NASDAQ:SCLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
US |
|
Shenwan Hongyuan Group Co Ltd
SZSE:000166
|
CN |
|
TechPrecision Corp
NASDAQ:TPCS
|
US |
|
Eastroc Beverage Group Co Ltd
SSE:605499
|
CN |
|
Nice Ltd
NASDAQ:NICE
|
IL |
|
Creo Medical Group PLC
LSE:CREO
|
UK |
|
Akeso Inc
HKEX:9926
|
CN |
|
V
|
Vincenzo Zucchi SpA
MIL:ZUC
|
IT |
|
Shinnihon Corp
TSE:1879
|
JP |
|
Pierce Group AB (publ)
STO:PIERCE
|
SE |
|
P
|
Protean eGov Technologies Ltd
BSE:544021
|
IN |
Scilex Holding Co
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
